Home > Oncology > ASCO 2020 > Gastrointestinal Cancer > Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC

Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC

Expert
Dr Philippe Merle, Groupement Hospitalier Lyon Nord, France
Conference
ASCO 2020
Trial
REFINE
An interim analysis of the REFINE study demonstrated that, in real-world practice, most patients receive regorafenib as second-line after sorafenib. Efficacy and safety of regorafenib were similar to those in the clinical trials in both the overall cohort and in patients who discontinued sorafenib. For patients with hepatocellular carcinoma (HCC) who are not or who are no longer candidates for locoregional therapy, systemic therapy with sorafenib is the current standard-of-care [1]. Recently, the RESORCE trial showed systemic treatment with regorafenib to be effective after progression on sorafenib [2]. The REFINE study was designed to evaluate the safety and effectiveness of second-line treatment with regorafenib in patients with HCC in real-world practice. This prospective, observational study aims to recruit 1,000 patients with unresectable HCC for whom a decision to treat with regorafenib was made by the treating physician prior to enrolment acc...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on